Navigation Links
Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL
Date:12/4/2008

HAE:TSX

MONTREAL, Dec. 4 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio-therapeutics company developing high-value, human plasma-derived protein products for commercialization, announces that is has confirmed the successful operation qualification of the fibrin sealant production equipment at its new state-of-the-art plasma fractionation facility in Sarasota, Florida.

"I am very excited that we have achieved the important milestone of operation qualification, thus showing clear progress in our transition from a development to a manufacturing company. This allows us to take steps towards the next milestone of producing clinical lots of our lead product candidate, human fibrin sealant, and advancing it to market", said Joseph Galli, Chairman and CEO of Haemacure. "Achieving this milestone also triggers the contractual obligation of CSL Behring AG to pay Haemacure US$1.5 million", concluded Mr. Galli.

The successful operation qualification of the production equipment is one of three milestones the achievement of which obligates CSL Behring AG ("CSL") to pay to Haemacure US$4.5 million in total, pursuant to a settlement agreement entered into in 2002 in relation to its Hemaseel project. The achievement of each milestone obligates CSL to pay Haemacure US$1.5 million. As previously announced, CSL has advised Haemacure that, in its view, it is no longer obligated to make the milestone payments. Haemacure strongly disputes the position of CSL and has, as a result, filed a request for arbitration with the International Court of Arbitration of the International Chamber of Commerce to assert its right to collect the contractual milestone payments and, in particular, the payment due upon the operation qualification of production equipment. Haemacure plans on achieving the second milestone during the first half of 2009 and the third milestone during the following 12 months.

Plasma pro
'/>"/>

SOURCE Haemacure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
2. Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors
3. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
4. Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
5. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
6. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
7. Haemacure Reports on Financing Progress and Second Quarter Results
8. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
9. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
10. Haemacure financing receives shareholder consent - Series B Warrants are amended
11. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009).../PRNewswire-FirstCall/--Jamba,Inc.(Nasdaq: JMBA )a...eEZ-2MAKE!JambaJuice(TM)SmoothieandIcePopMaker,aJa...ie-makingexperiencetochildrennationwide.Createdtog...ieandIcePopMakerwillbeavailableataleadingtoyretail...letoadditionalU.S.retailersbeginningJanuary2010. ,...
(Date:11/24/2009)...m Lintner is embracing the latest tools of virtual...oing dialogue with patients. Through Facebook, Twi...provides information about his Atlanta plastic su...that patients may have. , ...ic surgeon in Atlanta is taking full advantage of...
(Date:11/24/2009)...curity Launches EyeCentral Remote Video Platform f...thly Revenue for Central Stations and Security Dea...WEB) November 24, 2009 -- NCL Security Launches Ey...dustry to Generate Recurring Monthly Revenue for C...tegrated security systems has been and still is a ...
(Date:11/23/2009)... researchers from Virginia Commonwealth University...roxisomal oxidation of polyunsaturated fatty acids...lcoholic fatty liver (NAFL) to nonalcoholic steato...ntly higher plasma monounsaturated fatty acids in ...ndings appear in the December issue of Hepatology...
(Date:11/23/2009)...suffering from women,s hair loss for almost ten ye...e,s sharing her progress and the secret behind her... release of her video diaries which include a dire...eatment. , (PRWeb UK) Nov...sanett Siklosi has released the video diaries that...
Breaking Medicine News(10 mins):Health News:Jamba Juice and Think Wow Toys Bring the Smoothie Experience Home With Debut of Jamba Branded Toy Blender 2Health News:Jamba Juice and Think Wow Toys Bring the Smoothie Experience Home With Debut of Jamba Branded Toy Blender 3Health News:Atlanta Plastic Surgeon Using Social Media To Connect with Patients 2Health News:Atlanta Plastic Surgeon Using Social Media To Connect with Patients 3Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2Health News:Metobolomics uncovers key indicators of nonalcoholic fatty liver disease 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3
...gainst the re-use of device employed for root cana...fection in patients// with variant CJD. Research h...England’s, Chief Dental Officer, there have been n...ory Committee. This would be applicable to instrum...
...eems more of a burden for the women than a boon. T...e women not getting //the right kind of health car...ical bills on time in spite of having insurance. ...t the women patients don’t visit the specialist do...
...he key drivers behind the functioning of kidney di...Bottom line figures rule the roost, and these cent...alize higher hemoglobin levels in the patients. ...d endanger their lives. Abnormally high hemoglobin...
...ment therapy are more likely to be diagnosed with ...g //to a study published in the Lancet* today. ...he biggest study of its kind in the world, show th...one additional death from ovarian cancer. Th...
...ems to be following a familiar path. Taking a leaf...e subject of many debates and controversies, exper...on in the mandatory immunization programme for inf... become inevitable carriers of infection. Therefo...
...n bird flu samples, the World Health Organisation ...ctance //to send the samples could frustrate globa...ed human samples of the H5N1 virus with WHO collab...ek, the Ministry of Health informally told us that...
Other Medicine News:Health News:Costlier Health Care Weigh Downs the Women 2Health News:Costlier Health Care Weigh Downs the Women 3Health News:‘For-profit Dialysis Centers’ in the Spotlight Over Anti-anemia Drug Overdo 2Health News:HRT Increases Incidence and Deaths from Ovarian Cancer 2Health News:China Agrees to Share Bird Flu Samples 2
(Date:11/23/2009)...onewtherapiesforNon-Hodgkin,sLymphomas(NHL),theNCC...b(Azerra(TM),GlaxoSmithKline)asatherapyoptionforpa...psin(Istodax(R),GloucesterPharmaceuticals)asasugge...a(CTCL). ,, FORTWASHINGTON,Pa.,Nov.23/PRNewswir...eNationalComprehensiveCancerNetwork( NCCN )toupdat...
(Date:11/23/2009)...Reportlinker.comannouncesthatanewmarketresearchrep...Systems&Equipment-AGlobalMarketPerspective ,...zation-Systems--Equipment---A-Global-Market-Perspe...&utm_campaign=prnewswire ,, Steamsteril...rocedure.Steamsterilizationmarketisstableduetoregu...
(Date:11/23/2009)...Reportlinker.comannouncesthatanewmarketresearchrep...enDisposables-AWorldwideMarketReview ,, http...Disposables---A-Worldwide-Market-Review.html#utm_s...n=prnewswire ,, Withincreaseinrangeofinfect...eandhospitalfacilities,nonwovenshasemergedasagoldm...
Breaking Medicine Technology:NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 3Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 2Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 3Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 4Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 5Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 6Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 7Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 2Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 3Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 4Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 5Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 6Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 7Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 8BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 1BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 3BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 4BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 5Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies 14167 1Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies 14167 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 1Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 3Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 4Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 5Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 6Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 7Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 8
...Med, the Hutchison Whampoa backed pharmaceutical a...lts for its Phase II,proof-of-concept study for HM...orm of inflammatory bowel disease. The trial met,...and showed an,equivalent drop in clinical symptom ...ent first-line standard of care in,mild-to-moderat...
...- Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a ...sease and dermatology, today announced that,resear... Paul,Janmey and Dr. Robert Bucki, in collaboratio...ity, have demonstrated in a series,of in vitro exp...wn,as CSA-13 shows promise as a potential therapy ...
Other Medicine Technology:Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 2Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 3Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 4Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 5Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 6Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 7Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 8Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections 2Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections 3Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections 4
ScanGel® Incubator
... up to 12 mini gels under identical conditions in ... a time with the new Model 485 gradient former and... sources of variation and improving reproducibilit... convenience and reproducibility demanded by highe...
... up to 12 mini gels under identical conditions in ... a time with the new Model 485 gradient former and... sources of variation and improving reproducibilit... convenience and reproducibility demanded by highe...
...is system mirrors a 96-well plate in format, allow...ducts to take place easily and with direct compati...be carried out directly with a multi-channel pipet... off-set marker lanes are also included (one on ea...
Medicine Products: